General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated August 26, 2025
Status:
Concluded without agreement
Manufacturer:
Alexion Pharma GmbH
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated August 26, 2025
Status:
Concluded with an LOI
Manufacturer:
Apotex Inc.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Sandoz Canada Inc.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Biocon Biologics Canada Inc.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Organon Canada Inc.
Indication:
Multiple Indications
Last updated August 19, 2025
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor (FGFR)3 genetic alterations, who have disease progression during or following at least one line of prior therapy including within 12 months of neoadjuvant or adjuvant therapy.
Last updated August 13, 2025
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Primary hypercholesterolemia
Last updated August 13, 2025
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Primary hypercholesterolemia (non-familial and heterozygous familial)
Last updated August 13, 2025